Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Metabolite Profiling of [14C]-BIA 9-1067 in Healthy Males
NCT03119194Phase 1Completed
- Sponsor
- BIAL
- Start
- Jan 2017
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of opicapone in Parkinson's disease (PD), sponsored by BIAL. Primary endpoints: Mass balance recovery of total radioactivity in all (urine, faeces and expired air combined) amount excreted (Ae) up to 648 hours and Mass balance recovery of total radioactivity in all (urine, faeces and expired air combined) cumulative recovery (CumAe) up to 648 hours. Started Jan 2017; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03119194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03119194.